ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)

Lu, Shun; Wang, Jie; Cheng, Ying; Mok, Tony; Chang, Jianhua; Zhang, Li; Feng, Jifeng; Tu, Hai-Yan; Wu, Lin; Zhang, Yiping; Luft, Alexander; Zhou, Jian-Ying; Ma, Zhiyong; Lu, You; Hu, Chengping; Shi, Yuankai; Ying, Kejing; Zhong, Hua; Poddubskaya, Elena; Soo, Ross A.; Chia, Yee Hong; Li, Ang; Li, Amy; Wu, Yi-Long*复旦大学; 广东省人民医院; 四川大学; 郑州大学; 中国医学科学院; 中山大学; 1
Lung Cancer2021-2DOI: 10.1016/j.lungcan.2020.11.013
35被引5阅读
引用收藏
分享

摘要

Background: In the phase 3 CheckMate 078 study, nivolumab showed significant overall survival (OS) benefit and superior tolerability versus docetaxel in a predominantly Chinese patient population with non-small cell lung cancer (NSCLC). However, data on long-term outcomes with immunotherapy in Asian patients are limited. We report 2-year efficacy and safety data. @@@ Methods: Patients with advanced/metastatic NSCLC and disease progression after platinum-doublet chemotherapy were randomized 2:1 to nivolumab (3 mg/kg every 2 weeks; n = 338) or docetaxel (75 mg/m(2) every 3 weeks; n = 166) until progression, unacceptable toxicity, or other protocol-defined reasons. The primary endpoint was OS; secondary endpoints included progression-free survival, objective response rate, and safety. @@@ Results: After 25.9 months minimum follow-up, 21 patients (6 %) remained on nivolumab versus 0 on docetaxel. Median OS was 11.9 months with nivolumab versus 9.5 months with docetaxel (HR: 0.75; 95 % CI: 0.61-0.93); 2 year OS rates were 28 % versus 18 %, respectively. Survival benefits were observed across a variety of predefined subgroups. At 2 years, 39 % and 0 % of responders had ongoing responses with nivolumab and docetaxel, respectively. Grade 3-4 treatment-related adverse events occurred in 12 % of patients with nivolumab versus 47 % with docetaxel, leading to discontinuation in 4 % and 5 % of patients, respectively. No new treatment-related deaths occurred. @@@ Conclusion: At 2 years, nivolumab maintained a favorable safety profile and continued to demonstrate superior OS versus docetaxel in this predominantly Chinese patient population with previously treated NSCLC. These data are consistent with long-term outcomes from the global CheckMate 017/057 studies.

学科与关键词

关键词
Second-line NSCLCNivolumabAsianImmunotherapyPD-1 inhibitor
相关
加载中…
  • Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer
    Chang, Jianhua; Wu, Yi-Long; Lu, Shun; Wang, Jie; Mok, Tony; Zhang, Li; Feng, Jifeng; Wu, Lin; Tu, Hai-Yan; Zhang, Yiping; Luft, Alexander; Zhou, Jian-ying; Ma, Zhiyong; Lu, You; Hu, Chengping; Shi, Yuankai; Poddubskaya, Elena; Soo, Ross A.; Chia, Yee Hong; Penrod, John R.; Taylor, Fiona; Lawrance, Rachael; Blum, Steven, I; Sun, Xiaowu; Juarez-Garcia, Ariadna; Moreno-Koehler, Alejandro; Li, Ang; Li, Amy; Cheng, Ying*Lung Cancer, 2022, 165: 71-81.被引 8
  • An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870)
    Lu, Shun*; Cheng, Ying; Zhou, Jianying; Wang, Mengzhao; Zhao, Jun; Wang, Baocheng; Chen, Gongyan; Feng, Jifeng; Ma, Zhiyong; Wu, Lin; Wang, Changli; Ma, Kewei; Zhang, Shucai; Liang, Jun; Song, Yong; Wang, Jie; Wu, Yi-Long; Li, Ang; Huang, Yizhi; Chang, JianhuaTherapeutic Advances in Medical Oncology, 2022, 14.被引 2
  • Flat-dose nivolumab (NIVO) as second-line (2L) treatment (tx) in Asian patients (pts) with advanced non-small cell lung cancer (NSCLC): CheckMate 870 long-term results
    Lu, S.; Cheng, Y.; Zhou, J.; Wang, M.; Zhao, J.; Wang, B.; Chen, G.; Feng, J.; Ma, Z.; Wu, L.; Wang, C.; Ma, K.; Zhang, S.; Liang, J.; Song, Y.; Wang, J.; Wu, Y-L.; Li, A.; Huang, Y.; Chang, J.European Lung Cancer Congress (ELCC), ELECTR NETWORK, 2022-03-30 To 2022.
查看全部 →

发表信息

论文状态
公开发表
期刊
Lung Cancer
发表日期
2021-02
卷期
第 152 卷
页码
7-14
DOI
10.1016/j.lungcan.2020.11.013
语言
ENGLISH
期刊收录
NSL
期刊等级
2区
成果收录
SCIE
资助标注
Bristol Myers Squibb; Ono Pharmaceutical Company Ltd.

作者

  • L

    Lu, Shun (第一作者)

  • W

    Wang, Jie

    chinese acad med sci

查看全部 24 位作者收起作者
  • C

    Cheng, Ying

  • M

    Mok, Tony

    chinese univ hong kong

  • C

    Chang, Jianhua

    fudan univ

  • Z

    Zhang, Li

    sun yat sen univ

  • F

    Feng, Jifeng

  • T

    Tu, Hai-Yan

    guangdong prov peoples hosp

  • W

    Wu, Lin

    hunan canc hosp

  • Z

    Zhang, Yiping

    1 · zhejiang canc hosp

  • L

    Luft, Alexander

  • Z

    Zhou, Jian-Ying

    1

  • M

    Ma, Zhiyong

    zhengzhou univ

  • L

    Lu, You

    sichuan univ

  • H

    Hu, Chengping

  • S

    Shi, Yuankai

    chinese acad med sci

  • Y

    Ying, Kejing

  • Z

    Zhong, Hua

  • P

    Poddubskaya, Elena

  • S

    Soo, Ross A.

    1

  • C

    Chia, Yee Hong

  • L

    Li, Ang

  • L

    Li, Amy

  • W

    Wu, Yi-Long (通讯)

    guangdong prov peoples hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417